Given that EGFR and MUC1 expression was present in a large patient population, our work has shed light on the prospects of developing EGFR-MUC1 dual-targeting therapies, such as bispecific antibodies and ADCs, which might broaden the tumor selectivity while reducing the side-effects on normal organs. This evidence concerns the gene EGFR and neoplasm.